What Is the TULSA Prostate Treatment Success Rate?

TULSA, which stands for transurethral ultrasound ablation, achieves cancer control in roughly 65 to 85 percent of men with localized prostate cancer at the one-year mark, depending on how strictly success is defined. A recent meta-analysis pooling 13 studies and 650 patients found a universal technical success rate and an 85 percent reduction in PSA from baseline, with major complications occurring in only about 2 percent of cases. Those headline numbers look encouraging, but the full picture involves follow-up biopsies, five-year salvage rates, functional side effects, and how the treatment stacks up against surgery.

What TULSA Actually Does

TULSA delivers directional thermal ultrasound energy through a device inserted into the urethra while the patient lies inside an MRI scanner. The MRI provides real-time temperature mapping of the prostate, allowing the treating physician to see exactly which tissue is being heated and to steer the energy away from critical structures like the rectum and the urinary sphincter.¹ Preclinical safety work confirmed that this setup can confine cell death to the prostate with sub-millimeter accuracy, sparing surrounding tissue including the rectal wall and the external sphincter.²

The procedure is done under general anesthesia, typically takes a few hours including setup, and most patients go home the same day or the next morning. A catheter remains in place for roughly two weeks afterward, which is longer than after robotic surgery. The treatment can be tailored: physicians can ablate the entire gland (whole-gland treatment) or target only the region containing known cancer (focal or partial-gland treatment). That flexibility matters because the extent of ablation directly affects both cancer control and side-effect risk.

One-Year Cancer Control Numbers

The pivotal trial that led to FDA clearance enrolled 115 men with localized prostate cancer. The primary endpoint set by regulators was a PSA reduction of 75 percent or more, which was achieved in 96 percent of participants. Median PSA dropped by 95 percent, and the median prostate volume shrank from 37 cc to just 3 cc. On 12-month biopsy, 65 percent of men had no detectable cancer at all, and among those who entered the study with intermediate-risk disease, 79 percent were free of clinically significant cancer.³

Those two numbers, 65 percent completely cancer-free and 79 percent free of significant cancer, reflect different measuring sticks. A biopsy might still find a tiny speck of low-grade disease that wouldn’t threaten anyone’s life, so researchers track both. The five-year follow-up of the same cohort reported that 85 percent were free of clinically significant cancer at the one-year mark, with median prostate volume having decreased by 92 percent.⁴

A meta-analysis that pooled data across all published TULSA cancer studies found that biochemical recurrence occurred in about 13 percent of patients, clinically significant cancer was found on follow-up biopsy in about 22 percent, and roughly 14 percent ultimately needed some form of salvage treatment.⁵ Those pooled rates come with wide confidence intervals because the studies varied in patient selection, ablation extent, and follow-up duration. Still, they give a reasonable ballpark for what a newly treated patient can expect.

Five-Year Outcomes and Salvage Rates

The longer the follow-up window, the more honest the picture becomes, and five-year data from the pivotal trial shows that about one in five men eventually needed additional treatment. Specifically, 25 of 115 patients (roughly 22 percent) received salvage therapy over five years, including prostatectomy, radiation, hormone therapy, or a combination. No unexpected complications from those salvage procedures were reported, and median PSA at the five-year mark sat at 0.6 ng/mL among those who had not needed retreatment.⁶

An earlier phase I study with longer individual follow-up showed a similar pattern. Among 16 men with complete five-year data, median PSA held at 0.55 ng/mL, but 10 of the original cohort needed salvage therapy. The strongest predictors of needing further treatment were how much of the prostate had been ablated during the initial session and how low the PSA nadir went afterward. Men whose ablation covered less tissue and whose PSA didn’t drop as far were more likely to require a second intervention.⁷

A separate insurance claims analysis of ablative prostate therapies in the United States found that the five-year rate of any salvage treatment was between 22 and 25 percent across two large databases, with hormone therapy being the most commonly used salvage approach.⁸ The convergence of that real-world figure with the clinical trial data is reassuring: the trial results are not painting an artificially rosy picture.

The Trade-Off Between Ablation Extent and Side Effects

One of the defining tensions in TULSA is that more aggressive ablation improves cancer control but increases the risk of functional harm. A systematic review found that the planned ablation fraction was linearly related to salvage-free survival: treat more tissue and you’re less likely to need additional therapy. But the relationship between ablation extent and potency preservation followed a steep curve, meaning there’s a threshold beyond which erectile function drops off quickly.⁹

This is the fundamental clinical decision: whole-gland ablation gives the best cancer control but carries the most side-effect risk, while focal treatment preserves more function but leaves untreated tissue where cancer could recur. There’s no universal right answer. The choice depends on tumor location, how much of the prostate is involved, the patient’s baseline function, and how much uncertainty about recurrence the patient is willing to live with.

Side Effects and Functional Outcomes

Across the meta-analysis data, major complications (grade 3 or higher) occurred in about 2 percent of treatment-naive patients, and continence was preserved in 97 percent of men who had not previously been treated with radiation.¹⁰ That continence figure is considerably better than most prostate cancer treatment options, and it’s one of TULSA’s main selling points.

Erectile function is more variable. The early phase I trial reported that median erectile function scores at 12 months returned to roughly where they had been before treatment, with a mean change of just -1 point on a standardized scale.¹¹ But a more recent prospective trial painted a less optimistic picture: among 13 men who were potent before the procedure, seven experienced severe erectile dysfunction afterward. That same study also noted stress urinary incontinence in 6 patients and overactive bladder symptoms in 8.¹²

A single-center study using focal TULSA for localized cancer found no significant changes in continence or urinary symptoms over 12 months, though erectile function was significantly impaired at both 3-to-6 months and 9-to-12 months after treatment.¹³ The discrepancy between studies likely reflects differences in how aggressively the gland was treated and whether the ablation zone included the nerve bundles responsible for erections. When those bundles are spared, function recovery is much better; when they’re caught in the ablation zone, the outcomes look more like surgery.

How TULSA Compares to Robotic Prostatectomy

A randomized controlled trial comparing TULSA directly to robot-assisted radical prostatectomy (the most common surgical approach) has begun reporting perioperative data. Patients treated with TULSA had essentially no blood loss compared to a median of 100 mL with surgery, spent less than a day in the hospital versus more than one day for surgery, and reported less pain through the first week of recovery. Over the first month, TULSA patients were far less likely to report difficulty with mobility, self-care, or daily activities.¹⁴

The catch is that catheter duration was longer after TULSA (about 13 days versus 8 for surgery), and cancer-control outcomes from this randomized trial have not yet matured enough for head-to-head comparison. The recovery advantage is clear in the short term, but whether TULSA matches surgery for long-term cancer cure rates remains an open question. Prostatectomy removes the entire gland, so the cancer control ceiling is inherently higher. TULSA’s appeal is that it delivers something closer to that ceiling while preserving more quality of life, at least for the right patient.

What Happens If TULSA Fails

One of the practical concerns patients raise is whether TULSA burns any bridges. If cancer recurs after the procedure, can you still have surgery or radiation? The evidence is encouraging on this front. A study examining salvage radical prostatectomy after failed TULSA found that surgery was viable and safe, with negligible technical difficulty or added morbidity compared to a standard first-line prostatectomy. TULSA causes minimal scarring around the prostate, unlike radiation, which makes a subsequent surgical dissection much more straightforward.¹⁵

Repeat TULSA is also an option. A single-center retrospective series of 52 patients reported that 9 underwent a second TULSA session for residual or recurrent disease.¹⁶ This retreatability is a genuine advantage over radiation, which is essentially a one-shot treatment for the prostate. If TULSA underperforms, you still have the full menu of standard options ahead of you.

TULSA for Recurrent Cancer After Radiation

The salvage setting, treating cancer that has come back after prior radiation therapy, is a very different proposition from treating a fresh tumor. Radiation-damaged tissue is more fragile, less predictable, and harder to work with. TULSA has been tested in this scenario, and while feasibility is established, the complication profile is substantially worse than in treatment-naive patients.

A study with a median follow-up of about 40 months reported that 89 percent of salvage patients showed no cancer in the targeted area at 12 months, and median PSA dropped by 95 percent. Five-year metastasis-free survival was 97 percent. But severe complications occurred in 28 percent, including fistulas and two patients who ultimately needed bladder removal. Leak-free continence was preserved in only 53 percent, compared to 97 percent in treatment-naive patients.¹⁷ The cancer control numbers are encouraging in this population, but the functional toll is real and patients considering salvage TULSA need to weigh those risks carefully.

TULSA for Enlarged Prostate Without Cancer

Though most attention focuses on cancer, TULSA has also been studied for benign prostatic hyperplasia (BPH), the non-cancerous prostate enlargement that causes urinary obstruction in older men. The treatment is well suited for this because it can debulk the prostate from the inside, and it’s particularly useful for men who have both BPH symptoms and a concurrent prostate cancer diagnosis.¹⁸

A phase I BPH study reported an 82 percent improvement in symptom scores and a doubling of urinary flow rate at 12 months. All patients who had been taking BPH medications before the procedure stopped taking them afterward.¹⁹ A phase II study confirmed the pattern: symptom scores dropped from 17 to 4, maximum flow rate improved from about 11 to 18 mL per second, and quality-of-life scores improved substantially.²⁰ For men who need prostate volume reduction and want to avoid traditional surgery, TULSA offers a genuine alternative with durable symptom relief.

Who Is the Right Candidate

TULSA works best for men with low-to-intermediate risk localized prostate cancer that is confined to the gland. Men with high-volume or high-grade disease, tumors that have spread beyond the prostate capsule, or very large glands may not be ideal candidates. The procedure requires MRI visibility of the tumor and enough prostate anatomy to safely position the ultrasound device.

The factors that predict success or failure after TULSA have been consistent across studies: ablation coverage and PSA nadir. Men whose initial treatment covered the tumor-bearing region thoroughly and whose PSA dropped to very low levels were far less likely to need additional treatment.²¹ This means the quality of the initial treatment session matters enormously. A skilled center with experienced operators, good MRI guidance, and careful treatment planning will likely produce better outcomes than a site early on its learning curve.

Cost and Access in the United States

TULSA is not yet widely available. It requires an MRI suite configured for interventional procedures, the specialized TULSA device, and a team comfortable with the workflow, which limits it to select academic medical centers and specialized practices. An insurance claims analysis found that median total costs for ablative prostate therapies ran between roughly $22,000 and $24,500, with patient out-of-pocket costs in the range of $1,100 to $1,800.²² Coverage policies vary by insurer, and some patients may face significant out-of-pocket expenses depending on their plan. If you’re exploring TULSA, verifying insurance coverage early in the process will save you from surprises later.

The technology is still in its growth phase. As more randomized data emerge, especially long-term cancer outcomes from the ongoing TULSA-versus-surgery trial, expect both the evidence base and the number of treatment centers to expand. For now, TULSA occupies a promising middle ground between active surveillance and radical treatment, offering strong short-term cancer control and a lighter recovery footprint than surgery, while preserving the option to escalate if needed down the road.